Licenses and licensing conditions may vary from country to country. Please always consult your country specific SPC or package leaflet.
In the regular course of business, Baxter interacts and communicates directly with consumers, patients, health-care professionals, employees and others. These audiences may share their personally identifiable information with Baxter which we collect, store and process electronically and/or manually. Please see the following Global Privacy Principles that govern Baxter´s use of personally identifiable information ("Private Information"). Since Baxter has many websites developed by Baxter business units and regions that can be accessed via the www.baxter.com site, please also see the information provided in the section entitled "Baxter´s Website Policies" below.
IMPORTANT: Baxter´s Global Privacy Statement states: "In all instances, Baxter believes that it is a person´s right to have their personal information kept private. Therefore, we have an obligation to implement privacy procedures and technical security measures to keep personal information private and secure." If you should have any questions concerning Baxter´s privacy practices or wish to access or correct Private Information that Baxter has collected from you, please submit an inquiry via Baxters on-line Privacy Inquiry Form, call: 1-800-422-9837 (847-948-4770) or fax your inquiry to 847-948-3642.
Licenses and licensing conditions may vary from country to country. Please always consult your country specific SPC or package leaflet.
For additional resources, please click here.
| Product | Primary Uses | Product Description |
|
KIOVIG Human Normal Immunoglobulin (IVIg) |
Replacement therapy for primary and secondary immunodeficiencies, children with AIDS,
ITP, Guillain-Barré Syndrome, Kawasaki disease, and Allogeneic Bone
Marrow Transplantation
Please see SPC |
1mL contains 100 mg of IVIg solution for infusion |
|
GAMMAGARD S/D Human normal immunoglobulin (IVIg) |
Replacement therapy for primary and secondary immunodeficiencies, children with AIDS,
ITP, Guillain-Barré Syndrome, Kawasaki disease, and Allogeneic Bone
Marrow Transplantation
Please see SPC |
Solvent/detergent treated, sterile freeze dried preparation of highly purified IgG |
|
SUBCUVIA Human Normal Immunoglobulin for Subcutaneous Use |
Replacement therapy for adults and children with primary, secondary immunodeficiencies and recurrent infections
Please see SPC |
10% solution of polyvalent human normal immunoglobulin for subcutaneous infusion |
|
WinRho® SDF Human Anti-D (Rh0) Immunoglobulin |
Treatment of Immune Thrombocytopenic Purpura (ITP) in Rh0 (D) positive, non-splenectomised patients
Please see SPCs |
Powder and solvent for solution or injection |
|
TETABULIN S/D Human tetanus immunoglobulin for intramuscular use |
Post-exposure prophylaxis Therapy of clinically manifested tetanus Please see SPC |
Ready to use 16% solution for IM use |
|
PARTOBULIN SDF Human anti-D immunoglobulin for intramuscular use |
Prevention of Rh(D) immunisation in Rh(D) negative women
Please see SPC |
Ready-to-use 16% solution for 1mL use, one ml contains 1250 IU human anti-D immunoglobulin |
1ml contains 100 mg of IVIg solution for infusion
Please see SPC
Powder and solvent for solution containing 0.5g, 2.5g, 5g, and 10g IgG per vial
Please see SPC
16% solution of polyvalent human normal immunoglobulin for subcutaneous infusion
Please see SPC